featured
Targeting PD-L1 and PD-L2 Signaling Across the Spectrum of Classical Hodgkin’s
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. N Engl J Med. 2015;372(4):311-319.
- Armand P, Shipp MA, Ribrag V, et al. PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker Assessment. Paper presented at: American Society of Hematology 57th Annual Meeting & Exposition; December 5-8, 2015; Orlando, FL. Abstract 584.
- Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome [published online April 11, 2016]. J Clin Oncol. doi: 10.1200/JCO.2016.66.4482.